Structure Therapeutics (NASDAQ:GPCR) Trading Up 5.2% – Here’s Why

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) shot up 5.2% during mid-day trading on Tuesday . The stock traded as high as $65.86 and last traded at $66.5280. 127,418 shares changed hands during mid-day trading, a decline of 88% from the average session volume of 1,061,634 shares. The stock had previously closed at $63.25.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Citizens Jmp lifted their target price on Structure Therapeutics from $87.00 to $120.00 and gave the stock a “market outperform” rating in a report on Friday, December 12th. Citigroup reissued an “outperform” rating on shares of Structure Therapeutics in a research note on Friday, December 12th. Piper Sandler reiterated an “overweight” rating on shares of Structure Therapeutics in a report on Tuesday, October 28th. Morgan Stanley lifted their target price on shares of Structure Therapeutics from $120.00 to $125.00 and gave the stock an “overweight” rating in a research report on Friday, December 12th. Finally, Stifel Nicolaus upped their price target on shares of Structure Therapeutics from $50.00 to $90.00 and gave the company a “buy” rating in a research report on Monday, December 8th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $99.11.

Structure Therapeutics Trading Down 1.9%

The business has a fifty day moving average price of $41.18 and a two-hundred day moving average price of $28.21. The company has a market cap of $4.24 billion, a price-to-earnings ratio of -57.33 and a beta of -1.64.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.01). On average, analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current year.

Institutional Trading of Structure Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. State of Wyoming acquired a new stake in Structure Therapeutics during the second quarter valued at $28,000. EverSource Wealth Advisors LLC raised its stake in shares of Structure Therapeutics by 530.0% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock worth $30,000 after purchasing an additional 901 shares in the last quarter. Assetmark Inc. raised its stake in shares of Structure Therapeutics by 39.9% during the 2nd quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock worth $60,000 after purchasing an additional 820 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of Structure Therapeutics by 29.1% during the 2nd quarter. PNC Financial Services Group Inc. now owns 4,415 shares of the company’s stock valued at $92,000 after buying an additional 994 shares during the last quarter. Finally, ANTIPODES PARTNERS Ltd grew its stake in shares of Structure Therapeutics by 39.1% in the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 4,078 shares of the company’s stock valued at $114,000 after buying an additional 1,146 shares in the last quarter. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.